Compare Supplements

Investigational — NO approved dose. Phase-2 trials used once-weekly subcutaneous injection with stepwise escalation up to 4.8-6.0 mg maintenance. There is no approved regimen; do not self-dose an unapproved drug.

Any time

Once-weekly subcutaneous injection (investigational only)

Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)

Any time

Once-weekly subcutaneous injection (Mounjaro / Zepbound)

• Not a dietary supplement and not an approved drug — investigational; do not self-source grey-market vials
• Personal/family history of medullary thyroid carcinoma or MEN 2 (expected GLP-1-class thyroid C-cell warning)
• History of pancreatitis

• Oral medications (delayed gastric emptying)
• Insulin / insulin secretagogues (sulfonylureas)
• Other GLP-1 / incretin drugs

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• History of pancreatitis (use with caution / avoid)

• Oral contraceptives
• Insulin and sulfonylureas
• Oral medications generally